Drug Search Results
More Filters [+]

Minodronic acid

Alternative Names: minodronic acid, ono-5920, ym529
Latest Update: 2024-04-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: SQS Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Egypt | India | Japan

Approved Indications: None

Known Adverse Events: None

Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Minodronic acid

Countries in Clinic: China, Unknown Location

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Osteoporosis|Osteoporosis, Postmenopausal

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20220817

P3

Not yet recruiting

Osteoporosis

None

CTR20170793

P3

Not yet recruiting

Osteoporosis, Postmenopausal

None

CTR20180989

P1

Not yet recruiting

Osteoporosis, Postmenopausal

None

CTR20171286

P1

Not yet recruiting

Osteoporosis

None

Recent News Events